Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia Government and Australia’s National Reconstruction Fund Corporation (NRFC), joining existing backers like Hesta, Host Plus, CSL, and QIC. With this close, Brandon Capital has raised over A$1 billion in total.
This fund focuses on investing in emerging biomedical technologies that aim to translate scientific discoveries into high-growth companies dedicated to improving human health.
Recent successes include FDA approvals for therapies from George Medicines and EBR Systems, as well as Q-Sera’s approval in Japan. Notable investments from Fund Six include AdvanCell, PolyActiva, Myricx Bio, and CatalYm.
The firm supports over 30 companies and more than 270 skilled jobs in Australia, making a significant contribution to the manufacturing sector while fostering global collaboration and enhancing Australia’s research capabilities.
KEY QUOTES:
“We’re excited to welcome the National Reconstruction Fund Corporation to our sixth fund, joining HESTA, Hostplus, CSL, QIC and the WA Government. Closing at $439 million, BB6 is our largest fund to date, and we remain committed to advancing breakthrough biomedical innovations through our unwavering scientific rigour and disciplined capital allocation, in pursuit of exceeding our investors’ expectations.”
Dr Chris Nave, Co-Founder and Managing Partner at Brandon Capital
“Medical science has long development timelines, and it is important for the NRFC to make early and considered investments in the sector to attract the talent and capital that we will need to build our local commercialisation capabilities. If we want medical science jobs and industries to exist in Australia in ten years, we need to invest in them today.”
NRFC CEO David Gall
